News & Videos - LILLY AND CO - English

Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity PR Newswire INDIANAPOLIS, April 17, 2024 Tirzepatide achieved a mean apnea-hypopnea index reduction of up to 63% (about 30 fewer events per hour), meeting all primary and key secondary endpoints in two phase 3 clinical trials Tirzepatide meaningfully improved sleep apnea symptoms in those with moderate-to-severe OSA and obesity with and without PAP therapy, and based on...

Lilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results Announcement PR Newswire INDIANAPOLIS, April 16, 2024 INDIANAPOLIS , April 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2024 financial results on April 30, 2024 . Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 10 a.m. Eastern time ....

DoH Collaborates with Eli Lilly and World Obesity Federation on Obesity Prevention and Management PR Newswire ABU DHABI, UAE, March 28, 2024 In reflection of its commitment to enhance the health of community members, ABU DHABI , UAE, March 28, 2024 /PRNewswire/ -- The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, signed a Memorandum of Understanding (MoU) with Eli Lilly Suisse SA, a global pharmaceutical company, and the World Obesity Federation...

Thinking about trading options or stock in Intuit, Pinterest, Adobe, Eli Lilly, or Robinhood Markets? PR Newswire NEW YORK, March 14, 2024 NEW YORK , March 14, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INTU, PINS, ADBE, LLY, and HOOD. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different options trading strategies. The report shows all vital aspects of...

More than two-thirds of people with atopic dermatitis and skin of color experienced skin improvement in a first-of-its-kind lebrikizumab study PR Newswire INDIANAPOLIS, March 10, 2024 INDIANAPOLIS , March 10, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results from a first-of-its-kind study of lebrikizumab specifically designed for people with skin of color and moderate-to-severe atopic dermatitis, commonly called eczema. In this study, treatment with lebrikizumab, an...

U.S. Food and Drug Administration to Convene Advisory Committee Meeting to Discuss the TRAILBLAZER-ALZ 2 Study of Donanemab PR Newswire INDIANAPOLIS, March 8, 2024 INDIANAPOLIS , March 8, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) expects to convene a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) to discuss the Phase 3 TRAILBLAZER-ALZ 2 trial, which evaluated the efficacy and...

Lilly's Newest Phase of Get Better Campaign Challenges Misperceptions About Obesity Care PR Newswire INDIANAPOLIS, March 7, 2024 Two new films draw attention to the importance of treating obesity as a disease and the appropriate use of anti-obesity medications INDIANAPOLIS , March 7, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today launched the next phase of its Get Better corporate branding campaign with a new focus on obesity. Earlier this year, Lilly launched Get Better to...

Lilly Announces Details of Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting PR Newswire INDIANAPOLIS, March 5, 2024 INDIANAPOLIS , March 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that preclinical data for agents targeting Nectin-4, KRAS G12D, and BRM (SMARCA2) will be presented at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San Diego . The presentations will include new...

Lilly to Participate in Cowen's 44th Annual Health Care Conference PR Newswire INDIANAPOLIS, Feb. 20, 2024 INDIANAPOLIS , Feb. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in Cowen's 44th Annual Health Care Conference on March 6 , 2024. Anat Ashkenazi, executive vice president and chief financial officer, will take part in a fireside chat at 9:10 a.m., Eastern time . A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's...

Philip Johnson to Retire as Lilly Treasurer PR Newswire INDIANAPOLIS, Feb. 9, 2024 INDIANAPOLIS , Feb. 9, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that after more than 28 years, Philip Johnson , group vice president and treasurer, will retire from the company at the end of February to pursue a new professional opportunity. "Phil has had a meaningful impact on Lilly over the last 28 years," said Anat Ashkenazi, executive vice president and chief financial officer at...

Thinking about buying stock in Foghorn Therapeutics, Oscar Health, Eli Lilly And Co, Palo Alto Networks, or CN ENERGY GROUP? PR Newswire NEW YORK, Feb. 8, 2024 NEW YORK , Feb. 8, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FHTX, OSCR, LLY, PANW, and CNEY. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. FHTX:...

Lilly Reports Strong Fourth-Quarter 2023 Financial Results and Provides 2024 Guidance PR Newswire INDIANAPOLIS, Feb. 6, 2024 Revenue in Q4 2023 increased 28%. New Products (i) revenue grew by $2.19 billion to $2.49 billion in Q4 2023, led by Mounjaro and Zepbound. Growth Products (ii) revenue increased 9% to $5.27 billion in Q4 2023, led by Verzenio and Jardiance. Pipeline progress included FDA approval of Zepbound for adults with obesity or overweight with weight-related comorbidities and...

Thinking about trading options or stock in General Motors, Meta Platforms, Archer-Daniels-Midland, Eli Lilly, or Celestica? PR Newswire NEW YORK, Jan. 30, 2024 NEW YORK , Jan. 30, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GM, META, ADM, LLY, and CLS. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different options trading strategies. The report shows all...

Johna Norton to Retire as Lilly Executive Vice President of Global Quality PR Newswire INDIANAPOLIS, Jan. 25, 2024 INDIANAPOLIS , Jan. 25, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Johna Norton , executive vice president of Global Quality, will be retiring after 34 years of service with the company, effective July 31, 2024 . She will continue to serve at full capacity in her role and as a member of Lilly's Executive Committee until her retirement date. An...

Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting PR Newswire INDIANAPOLIS, Jan. 23, 2024 Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant, the first to receive gene therapy in the United States for a genetic form of hearing loss AK-OTOF is a gene therapy being developed for the...

Lilly Confirms Date and Conference Call for Fourth-Quarter 2023 Financial Results and 2024 Financial Guidance PR Newswire INDIANAPOLIS, Jan. 23, 2024 INDIANAPOLIS , Jan. 23, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2023 financial results and 2024 financial guidance on Feb. 6, 2024 . Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance and guidance. The...

Thinking about trading options or stock in TG Therapeutics, Microsoft, Eli Lilly And Co, Chevron, or Alcon? PR Newswire NEW YORK, Jan. 10, 2024 NEW YORK , Jan. 10, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TGTX, MSFT, LLY, CVX, and ALC. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different options trading strategies. The report shows all vital aspects of...

Lilly Launches End-to-End Digital Healthcare Experience through LillyDirect™ PR Newswire INDIANAPOLIS, Jan. 4, 2024 INDIANAPOLIS , Jan. 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced LillyDirect ™, a new digital healthcare experience for patients in the U.S. living with obesity, migraine and diabetes. LillyDirect offers disease management resources, including access to independent healthcare providers*, tailored support, and direct home delivery of select Lilly...

Lilly to Participate in J.P. Morgan Healthcare Conference PR Newswire INDIANAPOLIS, Jan. 2, 2024 INDIANAPOLIS , Jan. 2, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the 42nd Annual J.P. Morgan Healthcare Conference, Jan. 8-11 , 2024. David A. Ricks, Lilly's chair and CEO, will participate in a fireside chat on Jan. 9 at 5:15 p.m. Eastern time . A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website at...

Thinking about buying stock in Cingulate, Gracell Biotechnologies, Eli Lilly, ESSA Pharma, or Coherus Biosciences? PR Newswire NEW YORK, Dec. 27, 2023 NEW YORK , Dec. 27, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CING, GRCL, LLY, EPIX, and CHRS. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link. CING:...